Patent ID: 9066903
Filing Date: 2015-06-30
Classification: A61K,A61P

Abstract:
1. A method of treating a subject, comprising: a) providing: b) co-administering the 5-HT1A agonist in combination with the dopamine receptor agonist to the subject during a preconditioning period under conditions suitable for reducing the dopamine receptor agonist-induced dyskinesia; c) co-administering the 5-HT1A agonist in combination with the dopamine receptor agonist to the subject during a dosage optimization period, wherein dosage of the dopamine receptor agonist is gradually reduced until at least one symptom of the Parkinson's disease is re-emerges; and d) co-administering the 5-HT1A agonist in combination with the dopamine receptor agonist to the subject under conditions suitable for reducing the at least one symptom of the Parkinson's disease, while reducing the dopamine receptor agonist-induced dyskinesia, wherein dosage of the dopamine receptor agonist is below that of step b and above that of step c.